Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version 2.1

被引:64
|
作者
Cole, J. C. [1 ]
Lin, P. [1 ]
Rupnow, M. F. T. [2 ]
机构
[1] QualityMetric, Lincoln, RI 02865 USA
[2] Ortho McNeil Janssen Sci Affairs LLC, Titusville, NJ USA
关键词
MSQ; migraine; prophylaxis; MID; MCID; HEALTH-STATUS MEASURES; ITEM RESPONSE THEORY; INTRAINDIVIDUAL CHANGES; RELIABILITY; IMPACT; RESPONSIVENESS; PREVENTION; TOPIRAMATE; VALIDITY; SCORE;
D O I
10.1111/j.1468-2982.2009.01852.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To propose minimal important differences (MID) for the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1). To our knowledge (to date), no published MID values exist for the MSQ v2.1 in any population. Analyses were performed on data from two pivotal clinical trials of topiramate for migraine prevention (n = 916), as well as from the QualityMetric National Headache Survey (n = 1016). Analyses included both distribution- and anchor-based MID techniques as well as group- and individual-level MID values. Group-level anchor-based MID values ranged from 3.2 [Role Restrictive domain (RR)] to 7.5 [Emotional Functioning domain (EF)], setting the minimum level of appropriate MID (which can also aid with power analysis). Individual-level distribution-based MID values resulted in highly similar estimates from two large databases: median MID of 8.5 for RR, 9.2 for Role Preventive (RP) and 12.0 for EF. Finally, individual-level anchor-based MID values ranged from 5.0 (RR and RP domains) to 10.6 (EF). For group-level purposes of calculating power for future studies, an MID of 3.2, 4.6 and 7.5 for RR, RP and EF is recommended. For within-group analyses for analysing clinical trial efficacy of each patient's change with responder analyses, 5 points is necessary for RR. For RP and EF, ranges are recommended: 5.0 to 7.9 for RP and 8.0 to 10.6 for EF. These latter two domains tend to have more error in the MID, and thus a sensitivity analysis with both ends of the range should be used to confirm significant differences in responder analyses.
引用
收藏
页码:1180 / 1187
页数:8
相关论文
共 50 条
  • [21] Content validity of the Migraine-Specific Quality of Life Questionnaire version 2.1 electronic patient-reported outcome
    Rebecca M. Speck
    Huda Shalhoub
    David W. Ayer
    Janet H. Ford
    Kathleen W. Wyrwich
    Elizabeth N. Bush
    Journal of Patient-Reported Outcomes, 3
  • [22] Validating Migraine-Specific Quality of Life Questionnaire v2.1 in Episodic and Chronic Migraine
    Bagley, Christine L.
    Rendas-Baum, Regina
    Maglinte, Gregory A.
    Yang, Min
    Varon, Sepideh F.
    Lee, Jeff
    Kosinski, Mark
    HEADACHE, 2012, 52 (03): : 409 - 421
  • [23] Responder definition thresholds of the Migraine-Specific Quality of Life Questionnaire Version 2.1 domains for use in patients with episodic and chronic migraine
    Speck, Rebecca
    Yu, Ren
    Ford, Janet
    Ayer, David
    Akkala, Sreelatha
    Wyrwich, Kathleen
    QUALITY OF LIFE RESEARCH, 2019, 28 : S129 - S129
  • [24] Migraine-Specific Quality of Life QuestionnaireChinese version 2.1 (MSQv2.1-C): psychometric evaluation in patients with migraine
    Chang, Hao-Yuan
    Jensen, Mark P.
    Yang, Chih-Chao
    Lai, Yeur-Hur
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2019, 17 (1)
  • [25] CONFIRMATORY FACTOR ANALYSIS AND DIFFERENTIAL ITEM FUNCTIONING ANALYSIS OF THE MIGRAINE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE VERSION 2.1 IN CHRONIC MIGRAINEURS
    Rendas-Baum, R.
    Maglinte, G. A.
    DeRosa, M.
    Yang, M.
    Varon, S. F.
    VALUE IN HEALTH, 2010, 13 (03) : A142 - A142
  • [26] Development and validation of the Migraine-Specific Quality of Life Questionnaire
    Jhingran, P
    Osterhaus, JT
    Miller, DW
    Lee, JT
    Kirchdoerfer, L
    HEADACHE, 1998, 38 (04): : 295 - 302
  • [27] MSQ: Migraine-Specific Quality-of-Life QuestionnaireFurther Investigation of the Factor Structure
    Priti Jhingran
    Sonia M. Davis
    Lisa M. LaVange
    David W. Miller
    Ronald W. Helms
    PharmacoEconomics, 1998, 13 : 707 - 717
  • [28] Psychometric Evaluation of the Migraine-Specific Quality of Life Questionnaire (MSQ v2.1) Using Data From Phase 3 Clinical Trials in Patients With Chronic Migraine (CM) and Episodic Migraine (EM)
    Stokes, Jonathan
    Dodick, David
    Lipton, Richard
    Whalley, Diane
    Savva, Yulia
    Gelhorn, Heather
    Nelson, Lauren
    Yarr, Stuart
    Gandhi, Pranav
    NEUROLOGY, 2023, 100 (17)
  • [29] Development and testing of the Japanese version of the migraine-specific quality of life instrument
    Ohbu, S
    Igarashi, H
    Okayasu, H
    Sakai, F
    Green, J
    Heller, RF
    Fukuhara, S
    Patrick, DL
    QUALITY OF LIFE RESEARCH, 2004, 13 (08) : 1489 - 1493
  • [30] Migraine-specific quality of life questionnaire and relapse of medication overuse headache
    Stefano Caproni
    Elisa Bianchi
    Letizia M. Cupini
    Ilenia Corbelli
    Ettore Beghi
    Paolo Calabresi
    Paola Sarchielli
    BMC Neurology, 15